Long Term Follow-Up after Laparoscopic Management of Early Stage Endometrial Cancer

2009 ◽  
Vol 16 (6) ◽  
pp. S81-S82
Author(s):  
G. Siesto ◽  
A. Cromi ◽  
M. Serati ◽  
N. Piazza ◽  
F. Zefiro ◽  
...  
2008 ◽  
Vol 15 (6) ◽  
pp. 42S-43S
Author(s):  
S. Palomba ◽  
A. Falbo ◽  
T. Russo ◽  
R. Oppedisano ◽  
R. Mocciaro ◽  
...  

2011 ◽  
Vol 18 (6) ◽  
pp. S152
Author(s):  
B. Rabischong ◽  
D. Larrain ◽  
M. Canis ◽  
Le Bouëdec G ◽  
C. Pomel ◽  
...  

2013 ◽  
Vol 31 (31) ◽  
pp. 3951-3956 ◽  
Author(s):  
Mathias Onsrud ◽  
Milada Cvancarova ◽  
Taran P. Hellebust ◽  
Claes G. Tropé ◽  
Gunnar B. Kristensen ◽  
...  

Purpose This follow-up of a randomized study was conducted to assess the long-term effects of external beam radiation therapy (EBRT) in the adjuvant treatment of early-stage endometrial cancer. Patients and Methods Between 1968 and 1974, 568 patients with stage I endometrial cancer were included. After primary surgery, patients were randomly assigned to either vaginal radium brachytherapy followed by EBRT (n = 288) or brachytherapy alone (n = 280). Overall survival was analyzed by using the Kaplan-Meier method. A Cox proportional hazards model was used to estimate hazard ratios (HRs) with 95% CIs. We also conducted analyses stratified by age groups. Results After median 20.5 years (range, 0 to 43.4 years) of follow-up, no statistically significant difference was revealed in overall survival (P = .186) between treatment groups. However, women younger than age 60 years had significantly higher mortality rates after EBRT (HR, 1.36; 95% CI, 1.06 to 1.76) than the control group. The risk of secondary cancer increased after EBRT, especially in women younger than age 60 years (HR, 2.02; 95% CI, 1.30 to 3.15). Conclusion We observed no survival benefit of external pelvic radiation in early-stage endometrial carcinoma. In women younger than age 60 years, pelvic radiation decreased survival and increased the risk of secondary cancer. Adjuvant EBRT should be used with caution, especially in women with a long life expectancy.


2011 ◽  
Vol 18 (5) ◽  
pp. 589-596 ◽  
Author(s):  
Benoit Rabischong ◽  
Demetrio Larraín ◽  
Michel Canis ◽  
Guillaume Le Bouëdec ◽  
Christophe Pomel ◽  
...  

2011 ◽  
Vol 8 (4) ◽  
pp. 417-426
Author(s):  
Benoit Rabischong ◽  
Demetrio Larraín ◽  
Guillaume Le Bouëdec ◽  
Michel Canis ◽  
Christophe Pomel ◽  
...  

2009 ◽  
Vol 16 (6) ◽  
pp. S81
Author(s):  
B. Rabischong ◽  
M. Canis ◽  
G. Le Bouedec ◽  
C. Pomel ◽  
J-L Achard ◽  
...  

Dermatology ◽  
2021 ◽  
pp. 1-7
Author(s):  
Jurr Boer

<b><i>Background:</i></b> Patients with hidradenitis suppurativa (HS) are still often disappointed with the current treatments offered and there is a clear demand for more effective options. Since the late 1990s there has been a revival in the use of radiotherapy (RT) for different benign diseases, including HS. During the past 20 years one case series and some scattered case reports have described promising results of RT. <b><i>Objectives:</i></b> To evaluate the long-term efficacy of RT in early-stage HS. <b><i>Methods:</i></b> A postal survey-based long-term follow-up with simple factual questions of partly retrospective and partly contemporary characteristics was performed. Sixty-four patients (96 axillae), diagnosed with mild to moderate HS were irradiated with a orthovoltage unit with 100 kV, 3 mm Al or 200 kV, 0.5 Cu filtering, respectively. Four to six biweekly fractional doses ranging from 0.75 to 1 Gy up to a total dose of 6 Gy in one series, and in chronic cases followed by four daily fractions of 2 Gy up to a total dose of 14 Gy, were given. Late treatment toxicity and the rate of remission of the disease were evaluated. <b><i>Results:</i></b> The overall response rate of the survey was 64.1% with 40.6% (26/64) valid, complete questionnaires. In total, 40 axillae were irradiated in these 26 patients. After a median follow-up of 40 years (range 32–52) complete remission of the lesions occurred in 34 of the 40 sites (85%). None of the 26 patients with 40 irradiated sites reported adverse effects at the time of the survey. <b><i>Conclusions:</i></b> RT appears to be an effective treatment for early and mild HS in the majority of patients. In this case series, no side effects were reported after a median follow-up period of 40 years.


Sign in / Sign up

Export Citation Format

Share Document